References

1.		Catlin, DH, Murray, TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA 1996; 276:231.
2.		Parkinson, AB, Evans, NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006; 38:644.
3.		US Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed, Williams and Wilkins, Baltimore 1996.
4.		Miller, KE, Hoffman, JH, Barnes, GM, et al. Adolescent anabolic steroid use, gender, physical activity, and other problem behaviors*. Subst Use Misuse 2005; 40:1637.
5.		Curry, LA, Wagman, DF. Qualitative description of the prevalence and use of anabolic androgenic steroids by United States powerlifters. Percept Mot Skills 1999; 88:224.
6.		Korkia, P, Stimson, GV. Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med 1997; 18:557.
7.		Lambert, MI, Titlestad, SD, Schwellnus, MP. Prevalence of androgenic-anabolic steroid use in adolescents in two regions of South Africa. S Afr Med J 1998; 88:876.
8.		DuRant, RH, Rickert, VI, Ashworth, CS, et al. Use of multiple drugs among adolescents who use anabolic steroids [see comments]. N Engl J Med 1993; 328:922.
9.		Eaton, DK, Kann, L, Kinchen, S, et al. Youth risk behavior surveillance--United States, 2005. MMWR Surveill Summ 2006; 55:1.
10.		Hershberger, LG, Shipley, EG, Meyer, RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83:175.
11.		Chang, C, Kokontis, J, Liao, S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240:324.
12.		Darimont, BD, Wagner, RL, Apriletti, JW, et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 1998; 12:3343.
13.		Leder, BZ, Longcope, C, Catlin, DH, et al. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000; 283:779.
14.		King, DS, Sharp, RL, Vukovich, MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial [see comments]. JAMA 1999; 281:2020.
15.		Brown, GA, Vukovich, MD, Martini, ER, et al. Endocrine responses to chronic androstenedione intake in 30- to 56-year-old men. J Clin Endocrinol Metab 2000; 85:4074.
16.		Acacio, BD, Stanczyk, FZ, Mullin, P, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. Fertil Steril 2004; 81:595.
17.		Wallace, MB, Lim, J, Cutler, A, Bucci, L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc 1999; 31:1788.
18.		Bhasin, S, Storer, TW, Berman, N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men [see comments]. N Engl J Med 1996; 335:1.
19.		Broeder, CE, Quindry, J, Brittingham, K, et al. The andro project: physiological and hormonal influences of androstenedione supplementation in men 35 to 65 years old participating in a high-intensity resistance training program. Arch Intern Med 2000; 160:3093.
20.		Knuth, UA, Maniera, H, Nieschlag, E. Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 1989; 52:1041.
21.		PETERA, V, BOBEK, K, LAHN, V. Serum transaminase (GOT, GPT) and lactic dehydrogenase activity during treatment with methyl testosterone. Clin Chim Acta 1962; 7:604.
22.		Cabasso, A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994; 26:2.
23.		Pope, HG Jr, Katz, DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994; 51:375.
24.		Hausmann, R, Hammer, S, Betz, P. Performance enhancing drugs (doping agents) and sudden death--a case report and review of the literature. Int J Legal Med 1998; 111:261.
25.		Kennedy, MC, Lawrence, C. Anabolic steroid abuse and cardiac death. Med J Aust 1993; 158:346.
26.		Payne, JR, Kotwinski, PJ, Montgomery, HE. Cardiac effects of anabolic steroids. Heart 2004; 90:473.
27.		Hartgens, F, Cheriex, EC, Kuipers, H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 2003; 24:344.
28.		Thompson, PD, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165.
29.		Ferenchick, GS, Hirokawa, S, Mammen, EF, Schwartz, KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol 1995; 49:282.
30.		Stilger, VG, Yesalis, CE. Anabolic-androgenic steroid use among high school football players. J Community Health 1999; 24:131.
31.		Aitken, C, Delalande, C, Stanton, K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug Alcohol Depend 2002; 65:303.
32.		Catlin, DH, Cowan, DA. Detecting testosterone administration [editorial]. Clin Chem 1992; 38:1685.
33.		Perry, PJ, MacIndoe, JH, Yates, WR, et al. Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Clin Chem 1997; 43:731.
34.		Aguilera, R, Chapman, TE, Starcevic, B, et al. Performance characteristics of a carbon isotope ratio method for detecting doping with testosterone based on urine diols: controls and athletes with elevated testosterone/epitestosterone ratios. Clin Chem 2001; 47:292.
35.		New designer steroid detected in top athletes, News Hour Extra, November 5, 2003.
36.		Richman, J. Four indicted in BALCO case, Oakland Tribune, February 13, 2004.
37.		Handelsman, DJ. Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J Clin Endocrinol Metab 2006; 91:1646.
38.		Peddling drugs to the pedal pushers [editorial]. Lancet 1998; 352:415.
39.		Birkeland, KI, Stray-Gundersen, J, Hemmersbach, P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 2000; 32:1238.
40.		Berglund, B, Hemmingson, P. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers. Int J Sports Med 1987; 8:231.
41.		Jenkins, P. Doping in sport. Lancet 2002; 360:99.
42.		Vergouwen, PC, Collee, T, Marx, JJ. Haematocrit in elite athletes. Int J Sports Med 1999; 20:538.
43.		Gareau, R, Audran, M, Baynes, RD, et al. Erythropoietin abuse in athletes [letter]. Nature 1996; 380:113.
44.		Skibeli, V, Nissen-Lie, G, Torjesen, P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98:3626.
45.		Beullens, M, Delanghe, JR, Bollen, M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 2006; 107:4711.
46.		Berggren, A, Ehrnborg, C, Rosen, T, et al. Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J Clin Endocrinol Metab 2005; 90:3268.
47.		Dall, R, Longobardi, S, Ehrnborg, C, et al. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab 2000; 85:4193.
48.		Longobardi, S, Keay, N, Ehrnborg, C, et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J Clin Endocrinol Metab 2000; 85:1505.
49.		Rich, JD, Dickinson, BP, Merriman, NA, Thule, PM. Insulin use by bodybuilders [letter]. JAMA 1998; 279:1613.
50.		Labotz, M, Smith, BW. Creatine supplement use in an NCAA Division I athletic program. Clin J Sport Med 1999; 9:167.
51.		Smith, J, Dahm, DL. Creatine use among a select population of high school athletes. Mayo Clin Proc 2000; 75:1257.
52.		Graham, AS, Hatton, RC. Creatine: a review of efficacy and safety. J Am Pharm Assoc (Wash) 1999; 39:803.
53.		Dempsey, RL, Mazzone, MF, Meurer, LN. Does oral creatine supplementation improve strength? A meta-analysis. J Fam Pract 2002; 51:945.
54.		Koshy, KM, Griswold, E, Schneeberger, EE. Interstitial nephritis in a patient taking creatine [letter]. N Engl J Med 1999; 340:814.
55.		Edmunds, JW, Jayapalan, S, DiMarco, NM, et al. Creatine supplementation increases renal disease progression in Han:SPRD-cy rats. Am J Kidney Dis 2001; 37:73.

New Search

Contents

My UpToDate

Feedback

Help

Log Out

©2007 UpToDate^® • www.uptodate.com Licensed to UpToDate Guest Pass

SupportTag: [ecapp1003p.utd.com-217.113.23.28-87FA79DF1B-2579]